[ Back to EurekAlert! ] Public release date: 1-Aug-2012
[ | E-mail Share Share ]

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System

Change in drug regimen offers new hope in advanced breast cancer

Study published in New England Journal of Medicine

MAYWOOD, Il. - A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer.

The study found that combing two drugs that normally are each given as single agents significantly extended the lives of women with metastatic breast cancer. Kathy Albain, MD, a breast cancer specialist at Loyola University Medical Center, is among the main authors of the study.

The study found that women who initially took the drugs anastrozole and fulvestrant at the same time together lived more than six months longer than women who took anastrozole alone, with fulvestrant given later when the disease progressed.

"This study is the first to show that combination hormonal therapy alone without chemotherapy improves survival in advanced breast cancer," Albain said. "This most likely will change the standard of care for how we treat these patients."

First author is Rita Mehta, MD, of the University of California at Irvine.

Anastrozole (brand name, Arimidex®) is a pill that is taken daily. It is in a class of medications called aromatase inhibitors. It works by decreasing the amount of estrogen the body makes. (Estrogen fuels breast cancer.) Fulvestrant (brand name Faslodex®) is given by injection. It binds to estrogen receptors, thereby blocking the effect estrogen has on cancer cells.

The study included 707 postmenopausal women who had metastatic breast cancer that was hormone-receptor-positive. About half the women were randomly assigned to receive the standard regimen: treat first with anastrozole, and after the disease progresses, switch to fulvestrant. The other half were randomly assigned to receive anastrozole and fulvestrant in combination.

Women who received the standard regimen survived a median of 41.3 months. Women who received the two drugs in combination survived a median of 47.7 months.

Among women who received the standard regimen, it took a median of 13.5 months for the disease to progress. Among those who received the drugs in combination, it took 15 months before the disease progressed.

The combination treatment produced even greater benefits among women who had not previously taken tamoxifen.

Side effects generally were similar in both treatment groups, although only the combination group experienced the most severe side effects (one stroke and two pulmonary embolisms).

###

Albain is a professor in the Department of Medicine, division of Hematology/Oncology at Loyola University Chicago Stritch School of Medicine.

The study was conducted by the SWOG national clinical trials network and supported by grants from the National Cancer Institute and AstraZeneca.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.